Agilent and Sera Prognostics Enter Strategic Partnership
News Feb 15, 2013
Agilent Technologies Inc. and Sera Prognostics Inc. have announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications.
Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science.
Agilent is a leading provider of a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.
"By providing pivotal information to physicians, Sera's preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care," said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics.
Critchfield continued, "Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine."
"Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges," said Yvonne Linney, VP and general manager of Agilent's Life Science Solutions Division.
Linney continued, "Agilent instrumentation is at the forefront of driving high-throughput workflows for sample preparation and mass-spec analysis that is critical in the field of proteomics."
As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production.
The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis.
To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE
Human Minibrains reveal the Effects of Psychedelic SubstancesNews
By employing mass spectrometry-based proteomics to analyze cerebral organoids, scientists identified the effects of psychedelic substances in the brain.READ MORE
Osteoporosis Treatments Advanced by Mass Spectrometry TechniquesNews
Using advanced mass spectrometry technology, scientists have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.READ MORE